Table 1.

Effect of ERK1 antisense and sense oligonucleotide infusions (10 μg/d) on levels of ERK1, ERK2, and TH immunoactivity, and of ERK activity, with and without concomitant chronic morphine treatment

MorphineERK1 immunoreactivityERK2 immunoreactivityERK activityTH immunoreactivity
Vehicle100  ± 9 (15)100  ± 11 (15)100  ± 8 (10)100  ± 7 (7)
+106  ± 14 (6)95  ± 11 (6)154  ± 12* (10)158*1_a (8)
Sense (10 μg/d)96  ± 14 (6)109  ± 12 (6)n.a. 106  ± 10 (6)
+95  ± 6 (5)92  ± 8 (5)n.a. 130  ± 11* (6)
Antisense (10 μg/d)65  ± 16* (15)93  ± 13 (15)96  ± 6 (9)98  ± 10 (6)
+59  ± 18* (6)104  ± 8 (6)98  ± 9 (9)103  ± 8 (5)
  • F1_a Originally published in Berhow et al. (1995).

  • *p < 0.05 versus vehicle (− morphine treatment) by χ2 test.